Marisa Wexler, MS, senior science writer —

Vyvgart (efgartigimod) won approval in the U.K. as an add-on to standard therapy for adults with generalized myasthenia gravis (gMG) who are positive for acetylcholine receptor (AChR)-targeting antibodies. “We are pleased to announce this latest regulatory approval of Vyvgart, another exciting advancement toward our vision of making our…

Early and aggressive treatments tend to lead to better control of myasthenia gravis (MG) symptoms, a recent study reports. The study suggests MG patients given early treatment with high doses of the corticosteroid methylprednisolone directly into the bloodstream are more likely to have minimal disease manifestations. “The data presented…

Ultomiris (ravulizumab-cwvz) has been approved in Canada to treat adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor (AChR), the most common type of MG-causing antibody. The announcement came less than a year after Ultomiris was approved for the condition in the U.S., and…

A new mathematical tool that combines factors such as age at disease onset, sex, and clinical test results, could predict with high accuracy the risk of converting from ocular myasthenia gravis to the generalized form of the disease, a recent study reported. The study, “Dynamic…

Myasthenia Gravis News has brought you up-to-date coverage of the latest scientific research and developments in treatment related to myasthenia gravis (MG) throughout 2022. We look forward to continuing to serve as a resource for patients and their families, caregivers, clinicians and physicians, researchers, advocates, industry leaders, scientists…

An infection with parvovirus B19 may contribute to abnormal immune cell growth in people who have a thymoma, or thymus tumor, associated with myasthenia gravis (MG), a new study reports. “This study shows that B19V infection may cause B-cell proliferation and formation of ectopic GCs [germinal centers], subsequently leading…

More than one in three people with myasthenia gravis (MG) have clinically relevant depression, and a similar proportion have anxiety, a new large-scale analysis found. These rates are high, even compared with other autoimmune diseases, according to the researchers, who stressed the importance of providing care and support to…

CAN106, an investigational complement-inhibiting therapy being developed by CANbridge Pharmaceuticals, has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) as a potential treatment for myasthenia gravis (MG). The FDA gives orphan drug status to therapies that have the potential to treat rare disorders,…

The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have agreed to review applications seeking the approval of zilucoplan to treat generalized myasthenia gravis (gMG). UCB, the therapy’s developer, announced the FDA accepted its new drug application (NDA), requesting zilucoplan be approved to treat…

The high blood sugar levels that characterize diabetes may prompt immune cells to be activated that can drive and worsen myasthenia gravis (MG), a recent study suggests. These findings indicate that tightly controlling blood sugar levels may benefit MG patients who also have diabetes. The study, “Diabetes mellitus aggravates…